Crinetics Pharmaceuticals, Inc. announced the appointment of Chris Robillard to the newly created position of chief business officer. Mr. Robillard brings more than a decade of experience designing and implementing corporate development strategies to capitalize on growth opportunities for biopharmaceutical companies. Before joining Crinetics, Mr. Robillard served as VP and head of business development for Goldfinch Bio, where he worked with leaders across the organization to develop the corporate development strategy that incorporated partnering and funding opportunities.

Prior to that, at Karyopharm Therapeutics, he led business development and corporate strategy efforts, driving international expansion while transitioning from a clinical to commercial company.